NASDAQ · OSUR
OraSure Technologies, Inc.
$4.08-$0.02 (-0.49%)
OraSure Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.92% below the high.
Loading market information…
NASDAQ · PRE · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Prenetics Global Limited’s forward annual dividend is $2.80 per share, paid quarterly. The forward yield is 14.75% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Prenetics Global Limited’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.82. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Prenetics Global Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Jun 12, 2025 | -$0.800.0% vs estimate | $17.30M+44.17% vs estimate |
|---|
| Q4 2024 | Mar 5, 2025 | -$0.94-30.56% vs estimate | $10.50M-15.32% vs estimate |
|---|
| Q3 2024 | Nov 25, 2024 | -$0.84+2.33% vs estimate | $7.78M-15.46% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $40.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.08-$0.02 (-0.49%)
OraSure Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.92% below the high.
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
$5.86+$0.08 (+1.38%)
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.53% below the high.
$2.38+$0.12 (+5.31%)
Neuronetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.81% below the high.
$1.73+$0.02 (+1.17%)
MaxCyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.42% below the high.
$1.22-$0.04 (-3.17%)
Codexis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
$3.25-$0.04 (-1.22%)
Armata Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.3% below the high.
$3.18$0.00 (0.0%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.63% below the high.
